Trial Profile
A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Gontivimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Proof of concept
- Sponsors Ablynx
- 03 May 2016 Top-line results published in an Ablynx media release.
- 03 May 2016 Top-line results published in an Ablynx media release.
- 03 May 2016 Top-line results of ALX-0171 inhaled using Vectura's FOX device in hospitalised infants (n=53) published in the Vectura media release.